ReviewFrontiers in cardiovascular medicine2026
Caveolin-1 in atherosclerosis: from endothelial lipoprotein transport to vascular immunometabolic remodeling.
Review in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atherosclerosis is initiated by endothelial dysfunction and pathological retention of apolipoprotein B-containing lipoproteins within the arterial intima, yet the molecular mechanisms governing the earliest steps of lipoprotein entry remain incompletely understood. Caveolin-1 (Cav-1), the principal structural component of endothelial caveolae, has emerged as a critical regulator of vascular lipid transport, mechanotransduction, and inflammatory remodeling. However, its diverse and sometimes opposing biological functions have prevented a unified understanding of its role in atherosclerosis. In this review, we integrate recent advances regarding Cav-1-mediated regulation of atherogenesis, focusing on the transition from endothelial lipoprotein transport to vascular immunometabolic remodeling. We first discuss the structural and biochemical properties of caveolae and the scaffolding functions of Cav-1 that organize signaling and transport platforms. We then examine how Cav-1-dependent caveolar transcytosis facilitates receptor-guided low-density lipoprotein (LDL) transport through scavenger receptor class B type 1 (SR-B1), activin receptor-like kinase 1 (ALK1), and the DOCK4-RAC1 trafficking pathway, thereby controlling early lipid deposition in the arterial wall. Furthermore, we summarize how disturbed flow, glycocalyx disruption, and impaired autophagic turnover regulate Cav-1 abundance and localization, linking vascular biomechanics to lipid handling capacity. Importantly, we highlight the cell type- and disease stage-dependent effects of Cav-1. While endothelial Cav-1 promotes atherogenesis by enabling LDL transcytosis, macrophage Cav-1 deficiency may enhance Toll-like receptor 4/nuclear factor-
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.